title: Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats.
abstract: Recent in vivo and in vitro experiments have demonstrated that second-generation antipsychotic drugs (SGAs) might have neuroprotective effects. Ziprasidone is a SGA that is efficacious in the treatment of schizophrenia. In this study, we sought to analyze the effects of ziprasidone on the expression of the neuroprotective protein brain-derived neurotrophic factor (BDNF) in the rat hippocampus and neocortex, with or without immobilization stress. The effect of ziprasidone (2.5mg/kg) on the expression of BDNF mRNA was determined by in situ hybridization in tissue sections from the rat hippocampus and neocortex. Haloperidol (1.0mg/kg) was used for comparison. Haloperidol strongly decreased the expression of BDNF mRNA in both the hippocampal and cortical regions, with or without immobilization stress (p<0.01). In contrast, the administration of ziprasidone significantly attenuated the immobilization stress-induced decrease in BDNF mRNA expression in the rat hippocampus and neocortex (p<0.01). Ziprasidone exhibited differential effects on BDNF mRNA expression in the rat hippocampus and neocortex. These results suggest that ziprasidone might have a neuroprotective effect by recovering stress-induced decreases in BDNF mRNA expression.
authors.affiliation: Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea.
authors.forename: Sung Woo
authors.initials: SW
authors.lastname: Park
authors.forename: Chan Hong
authors.initials: CH
authors.lastname: Lee
authors.forename: Jung Goo
authors.initials: JG
authors.lastname: Lee
authors.forename: Sun Jung
authors.initials: SJ
authors.lastname: Lee
authors.forename: Na Ri
authors.initials: NR
authors.lastname: Kim
authors.forename: Sang Mi
authors.initials: SM
authors.lastname: Choi
authors.forename: Young Hoon
authors.initials: YH
authors.lastname: Kim
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects; D006220:Haloperidol / Q000008:administration & dosage / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D017403:In Situ Hybridization / Q000379:methods; D007274:Injections, Intraperitoneal; D008297:Male; D019579:Neocortex / Q000187:drug effects* / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012149:Restraint, Physical / Q000009:adverse effects; D013315:Stress, Psychological / Q000209:etiology / Q000503:physiopathology*; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D019208:Brain-Derived Neurotrophic Factor; D010879:Piperazines; D012333:RNA, Messenger; D013844:Thiazoles; C092292:ziprasidone; D006220:Haloperidol